The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Following the Trump administration's DEI ban, the FDA's move to scrub webpages has ensnared many pages focused on ensuring diversity in drug trials.

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...

Ultrasound BCI trials begin in UK as safer alternative to electrical stimulation UK starts clinical trials for a non-invasive brain technology to explore new treatment options ...